CoChat

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Open access
Cortés, Javier, Hurvitz, Sara A., Im, Seock-Ah, Iwata, Hiroji, Curigliano, Giuseppe, Kim, Sung-Bae, Chiu, Joanne W. Y., Pedrini, Jose L., Li, Wei, Yonemori, Kan, Bianchini, Giampaolo, Loi, Sherene, Borges, Giuliano S., Wang, Xian, Bachelot, Thomas, Nakatani, Shunsuke, Ashfaque, Shahid, Liang, Zhengkang, Egorov, Anton, Hamilton, Erika · 2024 · Nature Medicine
Cited by 169

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy endpoints (median follow-up, 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients)). The primary endpoint was progression-free survival (PFS) by blinded independent central review and was previously reported. The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, duration of response and PFS (all by investigator assessment) and safety. At data cutoff, 20 November 2023, median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24–0.38), the 36-month PFS rate was 45.7% versus 12.4% and median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94) with T-DXd versus T-DM1, respectively. Treatment-emergent adverse events were consistent with the previous analyses. No new instances of grade ≥3 interstitial lung disease or pneumonitis occurred (all grade rate, 16.7% (T-DXd) versus 3.4% (T-DM1)). With longer follow-up, T-DXd continued to demonstrate superior efficacy over T-DM1 with a manageable safety profile. ClinicalTrials.gov registration: NCT03529110.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03021-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 169

Metadata

Authors
Cortés, J., Hurvitz, S. A., Im, S.-A., Iwata, H., Curigliano, G., Kim, S.-B., Chiu, J. W. Y., Pedrini, J. L., Li, W., Yonemori, K., Bianchini, G., Loi, S., Borges, G. S., Wang, X., Bachelot, T., Nakatani, S., Ashfaque, S., Liang, Z., Egorov, A., & Hamilton, E.
Venue
Nature Medicine
Published
2024-06-02
Volume
30
Issue
8
Pages
2208-2215
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4399275893
Cited by
169
References
4
FWCI
25.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. https://app.cochat.ai/papers/10.1038/s41591-024-03021-7
The paper
Cortés, J., Hurvitz, S. A., Im, S.-A., Iwata, H., Curigliano, G., Kim, S.-B., Chiu, J. W. Y., Pedrini, J. L., Li, W., Yonemori, K., Bianchini, G., Loi, S., Borges, G. S., Wang, X., Bachelot, T., Nakatani, S., Ashfaque, S., Liang, Z., Egorov, A., & Hamilton, E. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03021-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.